Amneal Pharmaceuticals, Inc. (AMRX) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, and welcome to the AMNEW Pharmaceuticals Third Quarter 2025 Earnings Call. I will now turn the call over to AMNEW's Head of Investor Relations, Tony Daimio. Please go ahead. Good morning, and thank you for joining AMNEW Pharmaceuticals Third Quarter 2025 Earnings Call. Today, we issued a press release reporting Q3 results. The earnings press release and presentation are available at amneal.com. Certain statements made on this call regarding matters that are not historical facts, including but not limited to management's outlook or predictions, are forward-looking statements that are based solely on information that is now available to us. Please see the section entitled Cautionary Statements on Forward-Looking Statements for Factors that May Impact Future Performance. We also discuss non-GAAP measures. Information on use of these measures in reconciliation to GAAP are in the earnings release and presentation. On the call today are Chirag and Shintzu Patel, co-founders and co-CEOs, Tasos Ponideros CFO, our commercial leaders, Andy Boyer for affordable medicines, and Joe Renda for specialty. I will now hand the call over to Chirag. Thank you, Tony. Good morning, everyone. We are pleased with our strong third quarter performance. which represents another consecutive quarter of growth with revenues of $785 million and adjusted EBITDA of $160 million. At Amneal, we focus on delivering innovative and affordable medicines that make a difference for patients and providers. Since our founding in 2002, we have strategically expanded from generics into specialty, injectables, biosimilars, GLP-1, and complex medicines. This portfolio diversification has driven significant and sustainable top and bottom line growth. From 2019 through now, annual revenues have grown ...